Loading...
Loading...
NEW YORK, NY · CIK 0001263508
Portfolio Value
$10.20B
Positions
134
New
8
Increased
13
Decreased
19
Sold Out
9
BAKER BROS. ADVISORS LP (NEW YORK, NY) reported a portfolio value of $10.20B across 134 positions in their Q4 2016 SEC 13F filing (period ending 2016-12-31). The top 10 positions account for 83.9% of the portfolio.
Top 30 holdings by portfolio weight. Block width = holding percentage. Green = new/increased, red = reduced, gray = unchanged.
| # | Stock | Value↓ | Weight | Change |
|---|---|---|---|---|
| 1 | SGENEURSeattle Genetics, Inc. | $2.41B | 23.65% | +3.7% |
| 2 | INCYIncyte Corporation | $2.36B | 23.10% | +0.0% |
| 3 | ALXNAlexion Pharmaceuticals, Inc. | $800.57M | 7.85% | - |
| 4 | ACADACADIA Pharmaceuticals Inc. | $744.64M | 7.30% | - |
| 5 | Incyte Corporation | $558.65M | 5.48% | - |
| 6 | Incyte Corporation | $518.14M | 5.08% | - |
| 7 | GHDXGenomic Health, Inc. | $404.71M | 3.97% | - |
| 8 | BMRNBioMarin Pharmaceutical Inc. | $398.17M | 3.90% | - |
| 9 | DBV Technologies S.A. | $193.55M | 1.90% | - |
| 10 | Aquinox Pharmaceuticals, Inc. | $173.95M | 1.71% | - |
| Stock | Value | Shares |
|---|---|---|
| AveXis, Inc. | $15.05M | 315,300 |
| RIGLUSDRigel Pharmaceuticals, Inc. | $4.80M | 2,018,882 |
| BIIBBiogen Inc. | $4.68M | 16,500 |
| GNMXEURAevi Genomic Medicine, Inc. | $4.56M | 880,539 |
| RARXEURRa Pharmaceuticals, Inc. | $2.70M | 177,952 |
| CRBPEURCorbus Pharmaceuticals Holdings, Inc. | $2.20M | 260,129 |
| SBPHUSDSpring Bank Pharmaceuticals, Inc. | $1.75M | 219,298 |
| CBAYUSDCymaBay Therapeutics, Inc. | $535.00K | 309,268 |
Get alerts when BAKER BROS. ADVISORS LP files new 13F holdings.